ArsenalBio's Co-Founder & CEO Ken Drazan talks about engineering the next generation of T-cell therapies, including a clinical stage renal cell program that includes multiple features episode artwork

EPISODE · Jun 27, 2025 · 20 MIN

ArsenalBio's Co-Founder & CEO Ken Drazan talks about engineering the next generation of T-cell therapies, including a clinical stage renal cell program that includes multiple features

from BiotechTV - News · host BiotechTV

He describes the ArsenalBio's "CITE" platform, which allows it to make heterogenous cells by inserting modifications all in the same place. Plus, writing in logic gating, harnessing shRNA, and more. The company recently raised a $325M series C.

He describes the ArsenalBio's "CITE" platform, which allows it to make heterogenous cells by inserting modifications all in the same place. Plus, writing in logic gating, harnessing shRNA, and more. The company recently raised a $325M series C.

NOW PLAYING

ArsenalBio's Co-Founder & CEO Ken Drazan talks about engineering the next generation of T-cell therapies, including a clinical stage renal cell program that includes multiple features

0:00 20:31

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Frequently Asked Questions

How long is this episode of BiotechTV - News?

This episode is 20 minutes long.

When was this BiotechTV - News episode published?

This episode was published on June 27, 2025.

What is this episode about?

He describes the ArsenalBio's "CITE" platform, which allows it to make heterogenous cells by inserting modifications all in the same place. Plus, writing in logic gating, harnessing shRNA, and more. The company recently raised a $325M series C.

Can I download this BiotechTV - News episode?

Yes, you can download this episode by clicking the download button on the episode player, or subscribe to the podcast in your preferred podcast app for automatic downloads.
URL copied to clipboard!